ReviewFrontiers in pharmacology2026
Platelet mitochondria dysfunction in diabetes mellitus: mechanisms and therapeutic implications.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factor analysis and prediction of lower-extremity deep vein thrombosis after surgery in patients with non-small cell lung cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets play a pivotal role in hemostasis, thrombosis, and inflammation, and their dysfunction in diabetes significantly contributes to vascular complications such as ischemic stroke, myocardial infarction, and peripheral artery disease. This review explores the mechanisms underlying platelet hyperactivity in diabetes, emphasizing the critical involvement of platelet mitochondria. Hyperglycemia, insulin resistance, oxidative stress, advanced glycation end products, calcium dysregulation, and protein kinase C activation all converge to impair platelet mitochondrial function, leading to increased reactive oxygen species, altered bioenergetics, and defective mitophagy. These changes promote a pro-thrombotic and pro-inflammatory state, exacerbating vascular injury. Furthermore, the review highlights emerging therapeutic strategies targeting platelet mitochondria, including pharmacological agents, mitochondrial antioxidants, and even mitochondrial transplantation, to restore platelet function and mitigate vascular risks in diabetic patients. Understanding the intricate relationship between platelet mitochondria and diabetes opens new avenues for preventing and treating diabetic vascular complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.